<0.001 EU per 1 μg of the protein by the LAL method
Coagulation Factor IX Human
Factor IX is used to treat Christmas disease. Factor IX deficiency is treated by injection factor IX produced from human plasma. Tranexamic acid may be of value in patients undergoing surgery who have inherited factor IX deficiency in order to reduce the perioperative risk of bleeding.
Examples of Clinical Use:
Binds vitamin K and factor VIIIa. Cleaves the Arg-Ile bond in factor X to form active factor Xa. Plays a key role in blood coagulation and clotting. Injections of factor IX are used to treat hemophilia B, which is sometimes called Christmas disease. AlphaNine is injected to increase plasma levels of Factor IX and can temporarily correct this coagulation defect. The activated partial thromboplastin time (aPTT) is prolonged in people with hemophilia B. Treatment with factor IX concentrate may normalize the aPTT by temporarily replacing the factor IX. The administration increases plasma levels of factor IX, and can temporarily correct the coagulation defect in these patients.
Mechanism of action:
Coagulation Factor IX is an important protein in the process of hemostasis and normal blood clotting as it plays a key role within the coagulation cascade. It is located within the blood plasma as a zymogen, an antecedent to enzymatic function, in its inactivated state. Factor IX is dependent on the presence of Vitamin K, and is activated to a serine protease by the function of Coagulation Factor XIa. Factor XIa cleaves the peptide bond associated with protein activation in Factor IX, leaving Factor IX with two exposed chains, a light chain and a heavy chain. These two chains are held together by several disulfide bonds that reinforce the structure of Factor IX's activated form. After being activated, Factor IX forms a complex with calcium ions, membrane phospholipids and Coagulation Factor VIII to activate Coagulation Factor X. The activation of Factor X then performs a similarly integral step in the blood coagulation cascade. The ultimate result of phenotypically normal coagulation factors is the creation of platelets for normal blood clotting.
Coagulation Factor IX Human (F9) is an important coagulation protein, also known as coagulation factor IX, which is a key factor in the coagulation cascade and plays an important role in blood clotting and hemostasis. Clotting factor IX is a protein encoded by the F9 gene that is normally synthesized by the liver and released into the blood. Along with other clotting factors and phospholipids, it is involved in the complex process of blood clot formation. When blood vessels are damaged or tissue damaged, clotting factor IX is activated, participating in the intrinsic clotting pathway of the clotting cascade. In the internal clotting pathway, coagulation factor IX works with coagulation factor VIII and coagulation factor X to push the clotting cascade deeper, eventually leading to the formation of thrombin, which converts fibrinogen into fibrin and forms a blood clot. Clinically, Coagulation Factor IX Human can be used to treat Hemophilia B. For hemophilia B patients, due to the lack of coagulation factor IX in the body, exogenous supplementation of the coagulation factor IX protein can help restore coagulation function and prevent or control the occurrence of bleeding events. This treatment is usually given in the form of a clotting factor concentrate or a recombinant clotting factor IX protein to supplement the clotting factor that the patient lacks. In general, Coagulation Factor IX Human plays an important role in the treatment of hemophilia B, helping patients to recover the deficient clotting factor IX and reduce the risk of bleeding. This treatment usually needs to be carried out under the supervision and guidance of a professional physician to ensure efficacy and safety.
Clinical Application of Human F9 Protein
Coagulation Factor IX Human, which is used as a zymogenic, inactive precursor, undergoes a series of processes - removal of the signal peptide, glycosylation, and then cleavage by factor XIa or factor VIIa into a double-stranded form linked by disulfide bonds. Antithrombin inhibits F9, the expression of which increases with age in both humans and mice, and a lack of F9 can lead to hemophilia B. Of the more than 100 F9 mutants, some cause no symptoms, but many cause significant bleeding disorders. Recombinant F9 can be used to treat hemophilia B and is commercially available as BeneFIX and Alprolix. Some rare F9 mutations cause elevated clotting activity, leading to clotting disorders such as deep vein thrombosis.
Action Mechanism of Human F9 Protein
Coagulation Factor IX, also known as Factor IX or F9, is an important coagulation factor that plays a key role in the blood clotting process. Here's a brief explanation of how Factor IX works: (1) Activated coagulation cascade: When blood vessel injury leads to bleeding, activated platelets and damaged blood vessel walls release signaling substances that activate the coagulation cascade, and Factor IX is one of the important components of this reaction chain. (2) Activation of clotting Factor X: Factor IX is involved in the formation of thrombin complexes that activate clotting factor X through synergies with factor VIII and phosphatidylserine. (3) Activation of clotting factor X: The activation of clotting factor X is a key step in the clotting cascade, which further activates thrombin and promotes the conversion of fibrinogen into fibrin, which ultimately forms a thrombus. Overall, Factor IX acts as an integral part of the clotting cascade, facilitating the blood clotting process. Its lack or abnormality can lead to blood clotting dysfunction, such as hemophilia, so the proper function of Factor IX is essential for maintaining normal clotting function.
Advantages and Disadvantages of Human F9 Protein
Advantages (1) Hemophilia treatment: F9 is mainly used for the treatment of hemophilia B, because patients with hemophilia B lack effective F9 in the body, supplementing F9 can help restore blood coagulation function, thereby preventing and treating bleeding events. (2) Long history: As a traditional medicine for the treatment of hemophilia B, F9 has been fully verified for safety and effectiveness after long-term clinical application. (3) Targeted therapy: The targeted therapy of F9 can improve the quality of life of patients, reduce the risk of bleeding, and enable patients to better participate in normal life and daily activities. Disadvantages (1) Injection required: F9 usually needs to be administered by injection, which may be inconvenient and painful for patients to face. (2) High cost: Because the production and purification of the F9 process is more complex, and requires special conditions and equipment, resulting in high production costs, making the treatment cost relatively high. (3) Limitation of use: F9 is mainly suitable for the treatment of hemophilia B, and has limited therapeutic effect on other coagulation disorders or bleeding disorders.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.